[1] Fralick M, Jenkins AJ, Khunti K, et al. Global accessibility of therapeutics for diabetes mellitus[J]. Nat Rev Endocrinol, 2022, 18:199-204. doi: 10.1038/s41574-021-00621-y. [2] Päth G, Perakakis N, Mantzoros CS, et al. Stem cells in the treatment of diabetes mellitus - focus on mesenchymal stem cells[J]. Metabolism, 2019,90:1-15. doi: 10.1016/j.metabol.2018.10.005. [3] Trigo CM, Rodrigues JS, Camões SP, et al. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?[J]. J Adv Res, 2025,70:103-124. doi: 10.1016/j.jare.2024.05.004. [4] Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities[J]. Cell Stem Cell, 2018,22:824-833. doi: 10.1016/j.stem.2018.05.004. [5] Li H, Chen J, Han Q, et al. Histone methylation and microRNAs mediated regulation of the multipotential state of Flk1+ mesenchymal stem cells[J]. Sci Suppl, 2011, Selected presentations from the 2011 SINO-AMERICAN symposium. [6] 杨辰华.从“三焦-玄府”解析糖尿病气液病机与治则[J].中医研究,2021,34:9-12. [7] 安星燕,陈云飞,李娜,等.现代细胞生物学研究诠释三焦器官/间充质组织系统的医学实质[J].基础医学与临床,2018,38:1599-1605 [8] 张晓彤,赵月纯,朱镕嘉,等.以“肾-三焦”系统诠释间充质干细胞实质[J].基础医学与临床,2023,43:46-50. [9] Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis[J]. BMJ,2025,390:e083039. doi: 10.1136/bmj-2024-083039. [10] Shen MY, Li BR, Li YK. Silicon nanowire field-effect-transistor based biosensors: from sensitive to ultra-sensitive[J]. Biosens Bioelectron, 2014, 60:101-111. doi: 10.1016/j.bios.2014.03.057. [11] Krivitsky V, Zverzhinetsky M, Patolsky F. Redox-reactive field-effect transistor nanodevices for the direct monitoring of small metabolites in biofluids toward implantable nanosensors arrays[J]. ACS Nano, 2020, 14:3587-3594. doi: 10.1021/acsnano.9b10090. [12] Zhu R, Yan T, Feng Y, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms[J]. Cell Res, 2021,31:1244-1262. doi: 10.1038/s41422-021-00573-y. |